Cancer Genomic Profiling in Colorectal Cancer: Current Challenges in Subtyping Colorectal Cancers Based on Somatic and Germline Variants

被引:8
作者
Hinoi, Takao [1 ]
机构
[1] Hiroshima Univ Hosp, Dept Clin & Mol Genet, Hiroshima, Japan
来源
JOURNAL OF THE ANUS RECTUM AND COLON | 2021年 / 5卷 / 03期
关键词
cancer genomic profiling; colorectal cancer; molecular subtype; hereditary colorectal cancer syndrome; SUSCEPTIBILITY GENE-MUTATIONS; MIXED POLYPOSIS SYNDROME; WNT SIGNALING PATHWAY; MICROSATELLITE-INSTABILITY; PIK3CA MUTATION; BETA-CATENIN; ADJUVANT CHEMOTHERAPY; LYNCH SYNDROME; KRAS MUTATION; TARGET GENES;
D O I
10.23922/jarc.2021-009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Colorectal cancer (CRC) is a heterogeneous disease caused by the accumulation of multistep genetic alterations under the influence of genomic instability. Different backgrounds of genomic instability, such as chromosomal instability, microsatellite instability, hypermutated-single nucleotide variants, and genome stable-induced transformation in the colonic epithelium, can result in adenomas, adenocarcinomas, and metastatic tumors. Characterization of molecular subtypes and establishment of treatment policies based on each subtype will lead to better treatment outcomes and an improved selection of molecularly targeted agents. In Japan, cancer precision medicine has been introduced in the National Health Insurance program through the addition of the cancer genomic profiling (CGP) examination. It has also become possible to access a large amount of genomic information, including information on pathogenic somatic and germline variants, incomparable to conventional diagnostic tests. This information enables us to apply research data to clinical decision-making, benefiting patients and their healthy family members. In this article, we discuss the important molecules and signaling pathways presumed to be the driver genes of CRC progression and the signal transduction system in which they are involved. Molecular subtypes of CRC based on CGP examinations and gene expression profiles have been established in The Cancer Genome Atlas Network with the advent of next-generation sequencing technology. We will also discuss the recommended management of secondary/germline findings, pathogenic germline variants, and presumed germline pathogenic variants obtained from CGP examination and review the current challenges to better understand these data in a new era of cancer genomic medicine.
引用
收藏
页码:213 / 228
页数:16
相关论文
共 96 条
  • [1] CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
    Aasebo, Kristine
    Dragomir, Anca
    Sundstrom, Magnus
    Mezheyeuski, Artur
    Edqvist, Per-Henrik
    Eide, Geir Egil
    Ponten, Fredrik
    Pfeiffer, Per
    Glimelius, Bengt
    Sorbye, Halfdan
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [2] A prospective, multicenter, population-based study of BRAF mutational analysis for lynch syndrome screening
    不详
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (02) : 206 - 214
  • [3] Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B
    Asaka, Shin-ichi
    Arai, Yoshiko
    Nishimura, Yoji
    Yamaguchi, Kensei
    Ishikubo, Tsutomu
    Yatsuoka, Toshimasa
    Tanaka, Yoichi
    Akagi, Kiwamu
    [J]. CARCINOGENESIS, 2009, 30 (03) : 494 - 499
  • [4] BAKER SJ, 1990, CANCER RES, V50, P7717
  • [5] The serrated pathway to colorectal carcinoma: current concepts and challenges
    Bettington, Mark
    Walker, Neal
    Clouston, Andrew
    Brown, Ian
    Leggett, Barbara
    Whitehall, Vicki
    [J]. HISTOPATHOLOGY, 2013, 62 (03) : 367 - 386
  • [6] The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage
    Blaeker, Hendrik
    Alwers, Elizabeth
    Arnold, Alexander
    Herpel, Esther
    Tagscherer, Katrin E.
    Roth, Wilfried
    Jansen, Lina
    Walter, Viola
    Kloor, Matthias
    Chang-Claude, Jenny
    Brenner, Hermann
    Hoffmeister, Michael
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (03) : 455 - +
  • [7] Boland CR, 1998, CANCER RES, V58, P5248
  • [8] RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis
    Bond, Catherine E.
    McKeone, Diane M.
    Kalimutho, Murugan
    Bettington, Mark L.
    Pearson, Sally-Ann
    Dumenil, Troy D.
    Wockner, Leesa F.
    Burge, Matthew
    Leggett, Barbara A.
    Whitehall, Vicki L. J.
    [J]. ONCOTARGET, 2016, 7 (43) : 70589 - 70600
  • [9] Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer
    Bruun, Jarle
    Sveen, Anita
    Barros, Rita
    Eide, Peter W.
    Eilertsen, Ina
    Kolberg, Matthias
    Pellinen, Teijo
    David, Leonor
    Svindland, Aud
    Kallioniemi, Olli
    Guren, Marianne G.
    Nesbakken, Arild
    Almeida, Raquel
    Lothe, Ragnhild A.
    [J]. MOLECULAR ONCOLOGY, 2018, 12 (09) : 1639 - 1655
  • [10] Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1
    Buchanan, Daniel D.
    Stewart, Jenna R.
    Clendenning, Mark
    Rosty, Christophe
    Mahmood, Khalid
    Pope, Bernard J.
    Jenkins, Mark A.
    Hopper, John L.
    Southey, Melissa C.
    Macrae, Finlay A.
    Winship, Ingrid M.
    Win, Aung Ko
    [J]. GENETICS IN MEDICINE, 2018, 20 (08) : 890 - 895